prijavaregistracija

košarica

0.00 €
HPLC testiranoCOA vsaka serijaEU dostavaSEPA · varno plačiloResearch Use Only
PEPTIQA BIOTECHTirzepatide10 mgPurity 98.5% · RUO

Excellent

Ocena 5.0 / 5 — zgodnja ocena kakovosti

★Peptiqa Reviews

Zgodnja ocena kakovosti — po prvem verified nakupu lahko kupci objavijo mnenje.

Tirzepatide

10 mg98.5% purityLot #TIRZEP-2026-001

Šifra izbrane dimenzije: PEP-TIRZ-10MG

Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation. Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.
€267.18z DDV
✅ Na zalogi (40)

Količinski popusti

KoličinaCena / kosPrihranek
1 vial267.18 €—
3 vials (−7%)248.88 €−7%
5 vials (−12%)235.46 €−12%
Nakup & zberi 219 točk!

Ocene in mnenja

Prijavite se in ocenite izdelek po prejetem naročilu. prijava

Certifikat analize

Lab Verified
✓Ogled COA pred nakupom — transparentnost zagotovljena
Raziskovalni profil

Tirzepatide — znanstveni profil

Vsebina je namenjena izobraževalnim in raziskovalnim namenom. Research Use Only.

  • Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation.
  • Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.

Več iz kategorije Metabolizem

BPC-157
BPC-157
€114.68
TB-500
TB-500
€119.56
Glutathione
Glutathione
€87.84
GHK-Cu
GHK-Cu
€103.70

Ta stran uporablja piškotke

Accept